OxThera, based in Alachua, FL, is a biopharmaceutical company dedicated to developing novel treatments for rare kidney diseases, with a focus on primary hyperoxaluria. Their innovative approach aims to protect the kidneys from the damaging effects of high oxalate concentrations through the development of orally administered therapies like Oxabact.
Through partnerships with medical and patient communities, OxThera is at the forefront of research and development in the field of hyperoxaluria, with recent successful completion of Phase 3 studies and the granting of new patents for their product candidate Oxabact, marking significant progress in the treatment of primary hyperoxaluria.
Generated from the website